Millennium Management Reduces Stake in Sensei Biotherapeutics to 3.1%

Millennium Management LLC, along with Millennium Group Management LLC and Israel A. Englander, filed a Schedule 13G/A on June 2, 2026, regarding their holdings in Sensei Biotherapeutics, Inc. (SNSE). The filing reveals a significant reduction in their position, with beneficial ownership decreasing from 146,565 shares to 41,561 shares of common stock. This reduction brings their ownership interest down to 3.1% of the company, falling below the 5% reporting threshold typically required for active monitoring. The shares are held through various entities, including ICS Opportunities II LLC, over which Millennium Management LLC exercises investment discretion. The filing was made pursuant to Rule 13d-1(c), certifying that the shares were not acquired for the purpose of changing or influencing the control of the issuer. This amendment marks a notable decrease from their previously reported position.